Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Abstract Background Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) in metastatic renal cell carcinoma (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He, Pei Dong
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Renal cell carcinoma
Metastasis
Anti-PD-1 therapy
Targeted therapy
Stereotactic body radiation therapy
Medical physics. Medical radiology. Nuclear medicine
R895-920
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/3e0f90f743e142d0bc4168cf48440244
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/3e0f90f743e142d0bc4168cf48440244

Ejemplares similares